Social media peptide ads — UK rules

The three regimes

1. Human Medicines Regulations 2012 — Part 12 (POM advertising)

Direct-to-consumer advertising of prescription-only medicines is prohibited in the UK. For social-media peptide content this means:

• You cannot run a paid Instagram / TikTok ad naming Wegovy, Mounjaro, Ozempic, Saxenda, or Rybelsus as the product being offered.
• You cannot use an influencer post (with a material connection) to promote prescription of those products.
• Educational content explaining what GLP-1 medicines are is different — that’s editorial information, not POM advertising. The line is whether the communication promotes the use, prescription, or supply of the named product.

2. CAP code (non-broadcast) and BCAP code

The CAP code, enforced by the ASA, applies to all UK marketing communications — including organic social posts where a commercial relationship exists. For peptides, relevant sections:

• Section 12 — medicines, devices, and health. Claims must be substantiated; medicinal claims for unlicensed substances are prohibited.
• Section 13 — slimming. Specific rules on weight-loss claims, target audiences, required warnings.
• Section 5 — children. Peptide content cannot be marketed to under-18s or in ways likely to appeal to them.
• Section 3 — misleading advertising. Including before-and-after imagery and outcome claims.

3. Consumer Protection from Unfair Trading Regulations 2008 + CMA

The CPRs make misleading commercial practices a civil and (in some cases) criminal matter. The Competition and Markets Authority enforces influencer-disclosure rules. Undisclosed material connections are a per-se breach.

Organic vs paid — when does it count as advertising?

The trigger is a material connection between the poster and the brand or seller. Material connections include:

• Payment (any amount).
• Free product or services.
• Affiliate commission.
• Employment or contractor relationship.
• Equity in the brand.
• Family-business relationship.

Any of these triggers ASA jurisdiction and CPR disclosure obligations. A patient sharing their own GLP-1 experience with no commercial link is not advertising.

Platform-by-platform disclosure

Instagram

Paid partnership label (the platform-native flag), plus #ad or #sponsored at the top of the caption. Hashtag-only disclosure at the bottom of a long caption is not compliant.

TikTok

Branded Content disclosure toggle plus on-screen text or caption disclosure. TikTok’s short-format means disclosure has to be visible early in the video.

YouTube

Verbal disclosure within the first ~30 seconds, the “contains paid promotion” banner enabled, and written disclosure in the description.

Facebook

Paid partnership flag where available; otherwise clear disclosure in the post text. Facebook’s ad library captures paid content for transparency.

Telegram and Snapchat

No platform-native disclosure tools. Substantive disclosure in the post itself. Both platforms’ ephemeral / private formats are commonly used to evade disclosure entirely — that doesn’t make it lawful, it just makes enforcement harder.

What triggers enforcement

• Direct POM naming in paid social ads. Particularly Wegovy / Mounjaro / Ozempic — these are the active enforcement targets.
• Influencer posts promoting unlicensed peptides (BPC-157, TB-500, melanotan, etc.) with medicinal claims.
• Before-and-after imagery without substantiation.
• Specific weight-loss-number claims (“lose 2 stone in 12 weeks”).
• Undisclosed paid relationships, especially with unregulated supply.
• Funnel content — organic-looking posts that direct readers to off-platform unlicensed supply (DM, Telegram, etc.).

Reporting routes

• ASA: Make a complaint — covers all CAP code breaches across platforms.
• MHRA: Report a problem — for unlicensed-medicines issues and POM advertising breaches.
• CMA: Influencer disclosure issues fall under their consumer-protection remit.
• The platform: use the in-app report function for the post itself.